Molecular determinants of cell death induction following adenovirus-mediated gene transfer of wild-type p53 in prostate cancer cells

International Journal of Cancer

Volumn 91, Issue 2, 2001, Pages 159-166

  Schumacher, Guido ^a   Bruckheimer, Elizabeth M ^a   Beham, Alexander W ^a   Honda, Tsuyoshi ^b   Brisbay, Shawn ^a   Roth, Jack A ^b   Logothetis, Christopher ^a   McDonnell, Timothy J ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apoptosis; bcl 2; Gene therapy; p53; Prostate cancer

Indexed keywords

APOPTOSIS INDUCING FACTOR; MUTANT PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P21; PROTEIN P53; REGULATOR PROTEIN; VIRUS VECTOR;

ADENOVIRUS; APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; GENOTOXICITY; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION;

EID: 0035863549     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(200002)9999:9999<::AID-IJC1026>3.3.CO;2-E     Document Type: Article

References (71)

1. Gene therapeutics and gene therapy for cancer
2. Gene therapy for cancer: What have we done and where are we going
3. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by apoptosis
4. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer
5. Adenoviral-mediated gene transfer in advanced non-small cell lung cancer
6. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma
7. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers
8. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential
9. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma
10. The role of the p53 tumor suppressor gene in prostate cancer: A possible biomarker?
11. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases
12. p53 tumor suppressor gene mutations in benign prostatic hyperplasia and prostate cancer
13. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6
14. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
15. Radiation response of mouse lymphoid and myeloid cell lines
16. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
17. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers
18. Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis
19. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line
20. Bcl-2 blocks p53-dependent apoptosis
21. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles
22. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells
23. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer
24. Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation
25. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model
26. In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug
27. Bcl-2 suppresses apoptosis resulting from disruption of the NF-κB survival pathway
28. Bcl-2 inhibits p53 nuclear import following DNA damage
29. p21-containing cyclin kinases exist in both active and inactive states
30. p21 is a component of active cell cycle kinases
31. High efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus
32. Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis
33. p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation
34. Safety evaluation of Ad5CMV-p53 in vitro and in vivo
35. Characteristics of a human cell line transformed by DNA from human adenovirus type 5
36. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo
37. Bcl-2 confers androgen independence in androgen sensitive prostatic carcinoma
38. Molecular correlates of bcl-2-enhanced growth following androgen-ablation in prostate carcinoma cells in vivo
39. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen-independent prostate cancer
40. Bcl-2 protooncogene expression in normal, hyperplastic, and neoplastic prostate tissue
41. Bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer
42. Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells
43. Relationships between proto-oncogene expression and apoptosis induced by anticancer drugs in human prostate tumor cells
44. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death
45. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
46. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo
47. Overexpression of the Bcl-2 protein increases the half-life of p21Bax
48. Bax deficiency promotes drag resistance and oncogenic transformation by attenuating p53-dependent apoptosis
49. Bax suppresses tumorigenesis and stimulates apoptosis in vivo
50. Bcl-2/Bax: A rheostat that regulates an anti-oxidant pathway and cell death
51. Identification of a p53-dependent negative response element in the bcl-2 gene
52. L protein content in HT29 cells
53. The apoptosis-associated gamma-ray response of BCL-X(L) depends on normal p53 function
54. L protects cancer cells from p53-mediated apoptosis
55. L can confer a multidrug resistance phenotype
56. L promotes survival and mutagenesis after oxidative damage
57. L promotes susceptibility to mutagenesis
58. Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis
59. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair
60. Inhibition of cyclin-dependent kinases by p21
61. Cell-cycle arrest versus cell death in cancer therapy
62. CIP1/WAF1 by caspases is an early event during DNA damage-induced apoptosis
63. Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: Role of a caspase cascade
64. Overexpression of ErbB2 blocks taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase
65. Progression of LNCaP prostate tumor cells during androgen deprivation: Hormone-independent growth, repression of proliferation by androgen, and role for p27KIP1 in androgen-induced cell cycle arrest
66. Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter
67. Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation
68. Vogelstein B. Genetic determinants of p53-induced apoptosis and growth arrest
69. Induction of p21(WAF-1/CIP1) during differentiation
70. Activation of p21WAF1/Cip1 expression by a temperature-sensitive mutant of human p53 does not lead to apoptosis
71. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis